超個別化医療の世界市場2021-2031:機会分析・産業予測

【英語タイトル】Hyper Personalized Medicine Market By Product (Hyper Personalized Medicine Diagnostics, Hyper Personalized Medicine Therapeutics, Hyper Personalized Medical Care, Hyper Personalized Nutrition and Wellness), By Application (Oncology, Neurology, Blood Transfusion Safety, Diabetes, Autoimmune Diseases, Cardiology), By End User (Hospitals, Diagnostic Centers, Research and Academic Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料(ALD23JUN066)・商品コード:ALD23JUN066
・発行会社(調査会社):Allied Market Research
・発行日:2023年3月
・ページ数:280
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Online Only(1名閲覧、印刷不可)USD3,570 ⇒換算¥542,640見積依頼/購入/質問フォーム
Single User(1名閲覧)USD5,730 ⇒換算¥870,960見積依頼/購入/質問フォーム
Enterprise User(閲覧人数無制限)USD9,600 ⇒換算¥1,459,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

アライドマーケットリサーチ社の市場調査レポートでは、世界の超個別化医療市場規模が、2021年の2.1兆ドルから2031年には5.9兆ドルまで拡大し、2022年から2031年までの予測期間中、年平均成長率は11.7%を記録すると推測されています。当レポートでは、超個別化医療の世界市場について多面的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、製品別(超個別化医療診断、超個別化医療治療、超個別化医療ケア、超個別化栄養・ウェルネス)分析、用途別(腫瘍科、神経科、輸血安全性、糖尿病、その他)分析、エンドユーザー別(病院、診断センター、研究・学術機関、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ)分析、競争状況、企業情報などの内容を整理しています。なお、記載されている企業情報には、QIAGEN、Exagen Inc.、Abbott、Dako A/S、GE Healthcare、Illumina, Inc.、ASURAGEN, INC.、Exact Sciences Corporation、Danaher Corporation (Cepheid, Inc.)、Decode Genetics, Inc.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の超個別化医療市場規模:製品別
- 超個別化医療診断の市場規模
- 超個別化医療治療の市場規模
- 超個別化医療ケアの市場規模
- 超個別化栄養・ウェルネスの市場規模
・世界の超個別化医療市場規模:用途別
- 腫瘍科における市場規模
- 神経科における市場規模
- 輸血安全性における市場規模
- 糖尿病における市場規模
- その他用途における市場規模
・世界の超個別化医療市場規模:エンドユーザー別
- 病院における市場規模
- 診断センターにおける市場規模
- 研究・学術機関における市場規模
- その他エンドユーザーにおける市場規模
・世界の超個別化医療市場規模:地域別
- 北米の超個別化医療市場規模
- ヨーロッパの超個別化医療市場規模
- アジア太平洋の超個別化医療市場規模
- 中南米/中東・アフリカの超個別化医療市場規模
・競争状況
・企業情報

世界の超個別化医療市場は、2022年から2031年にかけて年平均成長率11.7%で、2021年の2.1兆ドルから成長し、2031年には5.9兆ドルに達すると予測されています。

単なる診断にとどまらず、患者ごとにターゲットを絞り、カスタマイズした治療法を開発することは、超個別化医療として知られています。超個別化医療には、DNAスクリーニングを通じて、症状が現れるかなり前に、希少で生命を脅かす可能性のある疾患を特定する能力があります。本質的には、このような高度な医療技術は、病気の治療だけでなく、病気になりやすい体質の予防にも役立つということです。
超個別化医療の手法は、がんの有病率の増加や臨床試験中の治療候補の増加により、世界中で高い需要があります。さらに、遺伝性疾患の発生率の増加は、超個別化医療市場の成長に大きな影響を与えると予測されています。超高スループットシーケンスや次世代シーケンシングといった技術の最近の進歩も、超個別化医療市場の成長率を押し上げると予測される重要な要因です。

これらの高度な医療技術の開発と実装にかかるコストが高いことが、超個別化医療市場における主な制約の1つです。このため、特に経済的に余裕のない人々や、医療施設が不十分な地域に住む人々など、特定の人々にはアクセスしにくい場合があります。また、患者データのプライバシーやセキュリティに対する懸念も、超個別化医療の採用に影響を与える可能性があります。
呼吸器疾患の増加、医療における急速な技術進歩、高齢化が、超個別化医療市場の成長を促進しています。さらに、ネブライザー、酸素濃縮器、加湿器などの治療用呼吸器デバイスの使用の増加が、業界の拡大を促進すると予測されています。WHOの予測によると、軽度から重度の慢性閉塞性肺疾患(COPD)で2019年に世界で320万人が死亡しました。さらにWHOの予測によると、COPDは世界第3位の死因であるとみられています。次世代シークエンシング(NGS)や高密度マイクロアレイなどの新たなゲノム技術の採用が増加し、政府のイニシアティブが後押しすることで、世界の遺伝子治療市場、ひいては超個別化医療市場が活性化すると期待されています。

COVID-19パンデミックは、超個別化医療市場に影響を与えました。超個別化医療市場は、COVID-19のパンデミックの影響を少なからず受けています。COVID-19は、患者や医療従事者がよりオーダーメイドのCOVID-19治療法や診断法を求めるようになり、オーダーメイド医療ソリューションに対する需要を高めました。その結果、個々の免疫系に合わせてカスタマイズできる予防接種の開発など、COVID-19に対する個別化医療アプローチの研究開発が増加しました。超個別化医療市場では、ゲノム、プロテオミクス、デジタルヘルスなどの最先端技術を応用して、遺伝的体質、生活習慣、健康歴に基づいて個人個人に合わせた治療を行います。この戦略は、医療費を削減しながら患者の予後を改善しようとするものです。パンデミックによってサプライチェーンが寸断され、臨床試験が妨げられ、医療予算が減少しており、これらすべてが超個別化医療市場の拡大を制限する可能性があります。

本レポートで紹介する主要企業は、QIAGEN、Exagen Inc.、Abbott、Dako A/S、GE Healthcare、Illumina, Inc.、ASURAGEN, INC.、Exact Sciences Corporation、Danaher Corporation(Cepheid, Inc.)、Decode Genetics, Inc.などです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの超個別化医療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、超個別化医療市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・超個別化医療市場の詳細なセグメンテーション分析により、市場機会を見極めます。
・各地域の主要国を、世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界別の超個別化医療の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
製品別
超個別化医療診断
超個別化医療治療
超個別化医療ケア
超個別化栄養&ウェルネス

用途別
がん領域
神経学
輸血安全性
糖尿病
自己免疫疾患
循環器内科

エンドユーザー別
その他
病院
診断センター
研究・学術機関

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
アラブ首長国連邦
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
QIAGEN
Exagen Inc.
Abbott
Dako A/S
GE Healthcare
Illumina, Inc.
ASURAGEN, INC.
Exact Sciences Corporation
Danaher Corporation (Cepheid, Inc.)
Decode Genetics, Inc.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Average Selling Price
3.7. Brand Share Analysis
3.8. Key Regulation Analysis
3.9. Market Share Analysis
3.10. Patent Landscape
3.11. Regulatory Guidelines
3.12. Value Chain Analysis
CHAPTER 4: HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Hyper Personalized Medicine Diagnostics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hyper Personalized Medicine Therapeutics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Hyper Personalized Medical Care
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Hyper Personalized Nutrition and Wellness
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Neurology
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Blood Transfusion Safety
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Diabetes
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Autoimmune Diseases
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Cardiology
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: HYPER PERSONALIZED MEDICINE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research and Academic Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: HYPER PERSONALIZED MEDICINE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Product
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Product
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Product
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Product
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Product
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Product
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. UK
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Product
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. France
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Product
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Spain
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Product
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Italy
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Product
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Product
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Product
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Product
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Product
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Product
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. South Korea
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Product
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. Australia
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Product
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Product
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Product
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Product
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. United Arab Emirates
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Product
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. Saudi Arabia
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Product
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. South Africa
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Product
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by End User
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Key market trends, growth factors and opportunities
7.5.5.5.2. Market size and forecast, by Product
7.5.5.5.3. Market size and forecast, by Application
7.5.5.5.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.2. Dako A/S
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.3. GE Healthcare
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.4. Illumina, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.5. ASURAGEN, INC.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.6. Exact Sciences Corporation
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.7. Danaher Corporation (Cepheid, Inc.)
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.8. Decode Genetics, Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.9. QIAGEN
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.10. Exagen Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 02. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2021-2031 ($BILLION)
TABLE 03. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2021-2031 ($BILLION)
TABLE 04. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICAL CARE, BY REGION, 2021-2031 ($BILLION)
TABLE 05. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED NUTRITION AND WELLNESS, BY REGION, 2021-2031 ($BILLION)
TABLE 06. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 07. HYPER PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2031 ($BILLION)
TABLE 08. HYPER PERSONALIZED MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021-2031 ($BILLION)
TABLE 09. HYPER PERSONALIZED MEDICINE MARKET FOR BLOOD TRANSFUSION SAFETY, BY REGION, 2021-2031 ($BILLION)
TABLE 10. HYPER PERSONALIZED MEDICINE MARKET FOR DIABETES, BY REGION, 2021-2031 ($BILLION)
TABLE 11. HYPER PERSONALIZED MEDICINE MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2031 ($BILLION)
TABLE 12. HYPER PERSONALIZED MEDICINE MARKET FOR CARDIOLOGY, BY REGION, 2021-2031 ($BILLION)
TABLE 13. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 14. HYPER PERSONALIZED MEDICINE MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($BILLION)
TABLE 15. HYPER PERSONALIZED MEDICINE MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($BILLION)
TABLE 16. HYPER PERSONALIZED MEDICINE MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($BILLION)
TABLE 17. HYPER PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)
TABLE 18. HYPER PERSONALIZED MEDICINE MARKET, BY REGION, 2021-2031 ($BILLION)
TABLE 19. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 20. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 21. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 22. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 23. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 24. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 25. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 26. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 27. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 28. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 29. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 30. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 31. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 32. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 33. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 34. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 35. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 36. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 37. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 38. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 39. UK HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 40. UK HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 41. UK HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 42. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 43. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 44. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 45. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 46. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 47. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 48. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 49. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 50. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 51. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 52. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 53. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 54. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 55. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 56. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 57. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 58. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 59. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 60. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 61. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 62. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 63. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 64. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 65. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 66. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 67. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 68. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 69. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 70. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 71. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 72. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 73. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 74. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 75. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 76. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 77. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 78. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 79. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
TABLE 80. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 81. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 82. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 83. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 84. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 85. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 86. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 87. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 88. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 89. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 90. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 91. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 92. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
TABLE 93. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
TABLE 94. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
TABLE 95. ABBOTT: KEY EXECUTIVES
TABLE 96. ABBOTT: COMPANY SNAPSHOT
TABLE 97. DAKO A/S: KEY EXECUTIVES
TABLE 98. DAKO A/S: COMPANY SNAPSHOT
TABLE 99. GE HEALTHCARE: KEY EXECUTIVES
TABLE 100. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 101. ILLUMINA, INC.: KEY EXECUTIVES
TABLE 102. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 103. ASURAGEN, INC.: KEY EXECUTIVES
TABLE 104. ASURAGEN, INC.: COMPANY SNAPSHOT
TABLE 105. EXACT SCIENCES CORPORATION: KEY EXECUTIVES
TABLE 106. EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT
TABLE 107. DANAHER CORPORATION (CEPHEID, INC.): KEY EXECUTIVES
TABLE 108. DANAHER CORPORATION (CEPHEID, INC.): COMPANY SNAPSHOT
TABLE 109. DECODE GENETICS, INC.: KEY EXECUTIVES
TABLE 110. DECODE GENETICS, INC.: COMPANY SNAPSHOT
TABLE 111. QIAGEN: KEY EXECUTIVES
TABLE 112. QIAGEN: COMPANY SNAPSHOT
TABLE 113. EXAGEN INC.: KEY EXECUTIVES
TABLE 114. EXAGEN INC.: COMPANY SNAPSHOT

★調査レポート[超個別化医療の世界市場2021-2031:機会分析・産業予測] (コード:ALD23JUN066)販売に関する免責事項を必ずご確認ください。
★調査レポート[超個別化医療の世界市場2021-2031:機会分析・産業予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆